Breast Cancer
Research on breast cancer reported by H.J. Au et al
Published in Cancer Weekly, April 14th, 2009
" BCIRG 001 demonstrated prolonged disease-free (DFS) and overall survival (OS) but increased toxicity for adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) in women with node positive breast cancer (BC). This study evaluates quality-adjusted survival and cost-effectiveness of adjuvant TAC versus FAC, taking downstream decisions and events into account, including palliative chemotherapy with taxanes," scientists in Edmonton, Canada report.
" We developed a Markov model for a cohort of women with node positive BC eligible for adjuvant anthracyclines. Data input included clinical and resource utilization...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-04-14)
More Articles from Cancer Weekly
- BG Medicine Inc.
BG Medicine Inc. Launches Galectin-3 Website and Commences Galectin-3 Assay Service for Clinical Research - Cancer
Palonosetron "Preferred" 5-HT3 Antagonist for Emesis Prevention in Oncology Patients Receiving Highly Emetogenic Chemotherapy - Cancer
Report Defines Need for Patients' Voice in Healthcare Reform - Cancer Gene Therapy
Data on cancer gene therapy detailed by researchers at University of Kuopio - Cancer Vaccines
Study results from M.A. Habel and colleagues in the area of cancer vaccines published - Celsion Corporation
Celsion Announces Promising ThermoDox® Clinical Results in Primary Liver Cancer Were Published in Expert Opinion - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
